We found that SB203580 and RPS6KA2-Sh synergistically inhibited p38/MAPK phosphorylation in ovarian cancer cells, while SB203580 partially rescued p38/MAPK activation caused by RPS6KA2-OE. This evidence concerns the gene RPS6KA2 and ovarian carcinoma.